VK2735: Comparing Viking’s Oral and Injectable Options
Viking Therapeutics is developing VK2735 in two forms, a weekly injection and a daily pill, and the practical difference comes down to convenience versus…
MariTide Results: How Much Weight Amgen’s Monthly Shot May Deliver
In its phase 2 trial, MariTide produced up to about 20% average weight loss over a year in people with obesity, and importantly, the…
Amycretin: Oral vs Injectable, and How Much Weight It May Help You Lose
Amycretin is unusual in that it’s being developed as both a daily pill and a weekly injection, and early data suggests the injection produces…
Survodutide for MASH: Treating Fatty Liver Disease and Obesity Together
Survodutide is being studied for a serious liver disease called MASH (metabolic dysfunction-associated steatohepatitis), and its early results are among the most promising in…
Is Orforglipron FDA Approved Yet? Timeline and What to Expect
Yes. Orforglipron was approved by the FDA on April 1, 2026, and is sold under the brand name Foundayo. It’s approved for adults with…
Orforglipron Side Effects: What Early Studies Report
Orforglipron, now FDA approved and sold as Foundayo, has a side-effect profile that looks a lot like injectable GLP-1 drugs despite being a pill:…
How Much Weight Can You Lose on CagriSema? Trial Results Explained
In its main obesity trial, CagriSema produced an average weight loss of about 22.7% over 68 weeks, which is among the highest seen for…
CagriSema Side Effects: What the Trials Show
CagriSema’s side effects are mostly gastrointestinal, and while they’re common, the large majority are mild to moderate and fade over time. In the phase…
Bimagrumab and GLP-1s: The Drug Studied to Preserve Muscle During Weight Loss
Bimagrumab is an unusual entry in the weight-loss world: it’s not a GLP-1 drug at all, but an antibody being studied to solve one…
